Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach

NCT01216644 is registered in ClinicalTrials.gov with Krankenhaus Nordwest as lead sponsor.

NCT NCT01216644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01216644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach
Lead sponsor
Krankenhaus Nordwest
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2010
Completion date
May 31, 2019
Enrollment
716 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer